ADMA logo

ADMA

ADMA Biologics Inc

$15.39
-$0.31(-1.97%)
48
Overall
55
Value
20
Tech
71
Quality
Market Cap
$3.46B
Volume
3.10M
52W Range
$13.76 - $25.67
Target Price
$30.00

Company Overview

Mkt Cap$3.46BPrice$15.39
Volume3.10MChange-1.97%
P/E Ratio17.5Open$15.32
Revenue$426.5MPrev Close$15.70
Net Income$197.7M52W Range$13.76 - $25.67
Div YieldN/ATarget$30.00
Overall48Value55
Quality71Technical20

No chart data available

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Sector: Healthcare
Industry: Biotechnology

Latest News

ADMA Biologics Announces CFO Transition and Leadership Change

The latest update is out from ADMA Biologics ( ($ADMA) ). In 2025, ADMA Biologics delivered record financial results, with total revenue reaching $...

TipRanks Auto-Generated Newsdesk11 days ago
ABCD
1SymbolPriceChangeVol
2ADMA$15.39-2.0%3.10M
3
4
5
6

Get ADMA Biologics Inc Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.